Achieving lipid goals with rosuvastatin compared with simvastatin in high risk patients in real clinical practice: a randomized, open-label, parallel-group, multi-center study: the DISCOVERY-Beta study

References

• BinbrekASElisAAl-ZaibagMfor the DISCOVERY Alpha Study Group2006Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: a randomized, open-label, parallel-group, multicenter study (DISCOVERY Alpha Study)Curr Ther Res672143
   PubMed Web of Science ®Google Scholar
• BotsAFEKasteleinJJP2005Achieving lipid goals in real life: the Dutch DISCOVERY StudyInt J Clin Pract5913879416351669
   PubMed Web of Science ®Google Scholar
• BrownWVBaysHEHassmannDR2002Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trialAm Heart J14410364312486428
   PubMed Web of Science ®Google Scholar
• CoreshJKwiterovichPOJr1996Small, dense low-density lipoprotein particles and coronary heart disease risk: a clear association with uncertain implicationsJAMA27691458782642
   PubMed Web of Science ®Google Scholar
• DavidsonMMaPSteinEA2002Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemiaAm J Cardiol892687511809427
   PubMed Web of Science ®Google Scholar
• De BackerGAmbrosioniEBorch-JohansenKOther Societies on Cardiovascular Disease Prevention in Clinical Practice2003Europen guidelines on cardiovascular disease prevention in clinical practiceEur Heart J2416011012964575
   PubMed Web of Science ®Google Scholar
• de LorgerilMSalenPMartinJ-L1999Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart StudyCirculation99779859989963
   PubMed Web of Science ®Google Scholar
• Estonian Medical Statistics Bureau1997Some facts about health care in Estonia 1992–1996Tallinn64
   Google Scholar
• Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)2001JAMA28524869711368702
   PubMed Web of Science ®Google Scholar
• FonsecaFAHRuizASilvaJM2005The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value – an Evaluation of Rosuvastatin therapY compared with atorvastatinCurr Med Res Opin2113071516083541
   PubMed Web of Science ®Google Scholar
• FriedewaldWTLevyRIFredricksonDS1972Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifugeClin Chem184995024337382
   PubMed Web of Science ®Google Scholar
• GottoAMJrGrundySM1999Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial data: issues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meetingCirculation99E1E710051310
   PubMedGoogle Scholar
• GuptaMConstanceC2005Direct statin comparison of LDL-C values: an evaluation of rosuvastatin therapy (DISCOVERY – Canada). [abstract]Atheroscler Suppl6108
   Web of Science ®Google Scholar
• HerregodsMCDaubresseJCMichelG2006DISCOVERY BELUX: An open-label, randomised, multi-centre, phase IIIb, parallel group study to compare the efficacy and safety of rosuvastatin and atorvastatin in subjects with type IIa and IIb hypercholesterolaemiaActa Cardiol612356
   Google Scholar
• ItoMKDeluccaGMAldridgeMA2001The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease related eventsJ Cardiovasc Pharmacol Ther61293511509919
   PubMedGoogle Scholar
• JonesPHDavidsonMHSteinEAfor the STELLAR Study Group2003Comparison of efficacy and safety of rosuvastatin versus ator-vastatin, simvastatin, and pravastatin across doses (STELLAR Trial)Am J Cardiol921526012860216
   PubMed Web of Science ®Google Scholar
• KnoppRH1999Drug treatment of lipid disordersN Engl J Med34149851110441607
   PubMed Web of Science ®Google Scholar
• LaksTTuomilehtoJJõesteE1999Alarmingly high occurrence and case fatality of acute coronary heart disease events in Estonia: results from the Tallinn AMI register 1991–94J Int Med2465360
   PubMed Web of Science ®Google Scholar
• LaRosaJCHunninghakeDBushDfor the Task Force on Cholesterol Issues, American Heart Association1990The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease: a joint statement by the American Heart Association and the National Heart, Lung, and Blood InstituteCirculation811721332184951
   PubMed Web of Science ®Google Scholar
• LevineGNKeaneyJFJrVitaJA1995Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanismsN Engl J Med332512217830734
   PubMed Web of Science ®Google Scholar
• Marques-VidalPFerrarioPKuulasmaaKfor the WHO MONICA Project1999Quality Assessment of Data on HDL Cholesterol in the WHO MONICA Project URL:http://www.ktl.fi/publications/monica/hdl/hdlqa.htm
   Google Scholar
• MiddletonAFuatA2006Achieving lipid goals in real life: the DISCOVERY-UK studyBr J Cardiol13726
   Web of Science ®Google Scholar
• OlssonAGIstadHLuurilaOon behalf of the Rosuvastatin Investigators Group2002Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemiaAm Heart J14410445112486429
   PubMed Web of Science ®Google Scholar
• PearsonTALauroraIChuH2000The lipid treatment assessment project (L-TAP): a multi-centre survey to evaluate the percentages of dyslipidemic subjects receiving lipid-lowering therapy and achieving low-density lipoprotein goalsArch Intern Med1604596710695686
   PubMed Web of Science ®Google Scholar
• ReddyKSYusufS1998Emerging epidemic of cardiovascular disease in developing countriesCirculation975966019494031
   PubMed Web of Science ®Google Scholar
• SansSKestelootHKromhoutDon behalf of the Task Force. The burden of cardiovascular diseases mortality in Europe1997Task Force of the European Society of Cardiology on cardiovascular mortality and morbidity statistics in EuropeEur Heart J18123148
   Web of Science ®Google Scholar
• SchusterHBarterPJStenderS2004Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) studyAm Heart J1477051215077101
   PubMed Web of Science ®Google Scholar
• SchusterH2003Rosuvastatin – a high effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10–40 mg doses in dyslipidemic patientsCardiology991263912824720
   PubMed Web of Science ®Google Scholar
• SleightP2003Current opinions in the management of coronary heart diseaseAm J Cardiol92Suppl4N8N
   PubMedGoogle Scholar
• StrandbergTEFeelyJSigurdssonEL2004Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: A DISCOVERY studyClin Ther2618213315639694
   PubMed Web of Science ®Google Scholar
• ThaulowEErikssenJSandvikL1993Initial clinical presentation of cardiac disease in asymptomatic men with silent myocardial ischemia and angiographically documented coronary artery disease (the Oslo Ischemia Study)Am J Cardiol72629338249835
   PubMed Web of Science ®Google Scholar
• ThomTJ1989International mortality from heart disease: Rates and trendsInt J Epidemiol18Suppl I208
   Google Scholar
• Tunstall-PedoeHKuulasmaaKMähönenMfor the WHO MONICA (monitoring trends and determinants in cardiovascular disease) Project1999Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populationsLancet35315475710334252
   PubMed Web of Science ®Google Scholar
• Tunstall-PedoeHKuulasmaaKTolonenH with 64 other contributors for the WHO MONICA Project2003MONICA Monograph and Multimedia SourcebookWorld′s largest study of heart disease, stroke, risk factors, and population trends 1979–2002GenevaWHO
   Google Scholar
• VartianenEPuskaPPekkanenJ1994Changes in risk factors explain changes in mortality from ischaemic heart disease in FinlandBr Med J3092378044063
   PubMedGoogle Scholar
• WoodDDe BackerGFaegermanO1998Task Force Report: Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and Other Societies on coronary preventionEur Heart J1914345039820987
   PubMed Web of Science ®Google Scholar
• ZhuJRTomlinsonBYoungMR2007A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study)Curr Med Res Opin2330556818196620
   PubMed Web of Science ®Google Scholar
• ZijlstraFPatelAJonesMfor the PCAT collaboration2002Clinical characteristics and outcome of patients with early (<2 h), intermediate (2–4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarctionEur Heart J235505711922645
   PubMed Web of Science ®Google Scholar